Industry Research Reports

Home > Reports > Machinery & Equipment > Global PRRS Vaccines Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032

Global PRRS Vaccines Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032

Industry: Machinery & Equipment

Published Date: 2026-03-09

Pages: 104 Pages

Report ld: 6049772

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

PRRS Vaccines Market Size(US$)

CAGR 2026-2032

3.5%

Market Size,2032

USD 543

Million

Market Snapshot

Market Size in 2026 (Value)

US$ 442 million

Market Forecast in 2032(Value)

US$ 543 million

CAGR

3.5%

Years Considered

2021-2032

Base Year

2026

Forecast Period

2026-2032

Source: Secondary research, interviews with experts, and QYResearch analysis

The global PRRS Vaccines market size was US$ 429 million in 2025 and is forecast to reach a readjusted size of US$ 543 million by 2032 with a CAGR of 3.5% during the forecast period 2026-2032.

There are two types of PRRS vaccines that are commercially available. One is a modified-live virus (MLV) vaccine and the other is a killed virus (KV) vaccine. PRRS MLV vaccine is well recognized for its protective efficacy against PRRSV that are genetically homologous to the vaccine virus.Porcine Reproductive and Respiratory Syndrome (PRRS) vaccine is a biological product designed to prevent and control PRRS, a highly contagious viral disease that affects pigs. The vaccine works by stimulating the pig's immune system to produce a protective response against the PRRS virus, thereby reducing reproductive failures such as abortions and stillbirths in sows, as well as respiratory illness and mortality in piglets and growing pigs. PRRS vaccines are typically classified into modified live vaccines (MLVs) and inactivated vaccines, and they play a critical role in improving herd health and productivity in the swine industry worldwide.

The global PRRS vaccine market is primarily driven by the widespread prevalence and economic impact of Porcine Reproductive and Respiratory Syndrome in the swine industry. PRRS is one of the most devastating diseases affecting pigs, causing significant reproductive losses in breeding herds and severe respiratory distress in growing pigs. The virus's ability to mutate and persist in herds has made it difficult to eradicate, leading to chronic infections and substantial financial losses for pig farmers. As a result, governments and veterinary authorities in major pork-producing countries such as China, the United States, and countries in the European Union have emphasized vaccination as a critical component of disease control programs. Additionally, rising global pork consumption is pressuring producers to maintain healthier herds and ensure consistent productivity, further boosting demand for effective PRRS vaccines. Technological advancements in vaccine formulation—such as the development of region-specific or genotype-specific modified live vaccines (MLVs)—have improved vaccine efficacy, making immunization a more reliable and widely accepted preventive measure. Moreover, increasing biosecurity awareness and the integration of vaccination into herd health management systems are reinforcing the growth of the PRRS vaccine market globally.

Despite its importance, the PRRS vaccine market faces several challenges that limit its effectiveness and adoption in certain regions. One of the primary issues is the virus's high genetic variability, which complicates the development of universally effective vaccines. The presence of multiple genotypes and frequent mutations means that vaccine strains may not provide cross-protection against all circulating variants, leading to inconsistent results and partial immunity in vaccinated herds. Additionally, modified live vaccines (MLVs), while generally more effective than inactivated ones, carry risks of reversion to virulence or recombination with field strains, which raises safety concerns among producers and regulatory bodies. In developing regions, limited access to veterinary services, cold chain logistics, and affordability issues further hinder the widespread adoption of PRRS vaccination programs. Moreover, there remains a lack of standardized vaccination protocols across countries, and vaccine performance can vary depending on farm conditions, pig genetics, and co-infections with other pathogens. These factors make disease management complex and can reduce confidence in vaccination strategies. Overcoming these challenges requires continued investment in research and development of next-generation vaccines, improved diagnostic tools for strain identification, and stronger government support for vaccination campaigns and swine health education.

The global PRRS Vaccines market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on sales, revenue, and forecasts across regions, by Type, and by Application for 2021-2032.

MARKET SEGMENTATION

By Company

China Animal Husbandry Co., Ltd.
Boehringer Ingelheim
MSD Animal Health
Sinopharm Animal Health
Ceva
Ruipu Biological
Qilu Animal Health
Dahuanong
CAVAC
Komipharm
Agrovet
Bioveta
Jinyu
Phibro Animal Health
Tiankang
Zoetis
Yongshun Biological
Pulike Biological

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Live Vaccines
Killed Vaccines

Segment by Application

Government Tender
Market Sales

biaoTi CHAPTER OUTLINE

Chapter 1: Report scope, segment-level executive summary (by Type, by Application) and market evolution across the short, mid and long term

Chapter 2: Quantitative analysis of PRRS Vaccines sales and revenue at global, regional, and country levels, highlighting market size and growth potential by region

Chapter 3: Competitive landscape of PRRS Vaccines manufacturers (sales, revenue, pricing, market share, industry rankings, and M&A / expansion plans)

Chapter 4: by Type-based segmentation analysis (sales, revenue, pricing, and growth potential) to identify blue-ocean product segments

Chapter 5: by Application-based segmentation analysis (sales, revenue, pricing, and growth potential) to uncover high-value downstream markets

Chapter 6: Regional breakdown by company, customer, by Type and by Application (sales, revenue, and pricing for each segment)

Chapter 7: Key manufacturer profiles –company overview, PRRS Vaccines product descriptions and specifications, revenue, gross margins, and recent developments

Chapter 8: Industry chain analysis – upstream raw materials, manufacturing links, and downstream application sectors

Chapter 9: Sales channels and distributor analysis – routes to market and key customer interfaces

Chapter 10: Market dynamics – trends, drivers, restraints, risks for manufacturers, and the impact of relevant industry policies

Chapter 11: Key findings, main takeaways, and overall conclusions of the report.

WHY THIS REPORT

Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the PRRS Vaccines value chain, addressing:

- Market entry risks/opportunities by region

- Product mix optimization based on local practices

- Competitor tactics in fragmented vs. consolidated markets

biaoTi QYRESEARCH'S STRENGTHS

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Market Overview

1.1 PRRS Vaccines Product Scope

1.2 PRRS Vaccines by Type

1.2.1 Global PRRS Vaccines Sales by Type (2021, 2025 & 2032)

1.2.2 Live Vaccines

1.2.3 Killed Vaccines

1.3 PRRS Vaccines by Application

1.3.1 Global PRRS Vaccines Sales Comparison by Application (2021, 2025 & 2032)

1.3.2 Government Tender

1.3.3 Market Sales

1.4 Global PRRS Vaccines Market Estimates and Forecasts (2021-2032)

1.4.1 Global PRRS Vaccines Market Size (Value) and Growth Rate (2021-2032)

1.4.2 Global PRRS Vaccines Market Size (Volume) and Growth Rate (2021-2032)

1.4.3 Global PRRS Vaccines Price Trends (2021-2032)

1.5 Assumptions and Limitations

2 Market Size and Prospects by Region

2.1 Global PRRS Vaccines Market Size by Region: 2021 VS 2025 VS 2032

2.2 Global PRRS Vaccines Historical Market Scenario by Region (2021-2026)

2.2.1 Global PRRS Vaccines Sales Market Share by Region (2021-2026)

2.2.2 Global PRRS Vaccines Revenue Market Share by Region (2021-2026)

2.3 Global PRRS Vaccines Market Estimates and Forecasts by Region (2027-2032)

2.3.1 Global PRRS Vaccines Sales Estimates and Forecasts by Region (2027-2032)

2.3.2 Global PRRS Vaccines Revenue Forecast by Region (2027-2032)

2.4 Major Regions and Emerging Market Analysis

2.4.1 North America PRRS Vaccines Market Size and Prospects (2021-2032)

2.4.2 Europe PRRS Vaccines Market Size and Prospects (2021-2032)

2.4.3 China PRRS Vaccines Market Size and Prospects (2021-2032)

2.4.4 Japan PRRS Vaccines Market Size and Prospects (2021-2032)

3 Global Market Size by Type

3.1 Global PRRS Vaccines Historical Market Review by Type (2021-2026)

3.1.1 Global PRRS Vaccines Sales by Type (2021-2026)

3.1.2 Global PRRS Vaccines Revenue by Type (2021-2026)

3.1.3 Global PRRS Vaccines Average Price by Type (2021-2026)

3.2 Global PRRS Vaccines Market Estimates and Forecasts by Type (2027-2032)

3.2.1 Global PRRS Vaccines Sales Forecast by Type (2027-2032)

3.2.2 Global PRRS Vaccines Revenue Forecast by Type (2027-2032)

3.2.3 Global PRRS Vaccines Price Forecast by Type (2027-2032)

3.3 Representative Players for Different Types of PRRS Vaccines

4 Global Market Size by Application

4.1 Global PRRS Vaccines Historical Market Review by Application (2021-2026)

4.1.1 Global PRRS Vaccines Sales by Application (2021-2026)

4.1.2 Global PRRS Vaccines Revenue by Application (2021-2026)

4.1.3 Global PRRS Vaccines Average Price by Application (2021-2026)

4.2 Global PRRS Vaccines Market Estimates and Forecasts by Application (2027-2032)

4.2.1 Global PRRS Vaccines Sales Forecast by Application (2027-2032)

4.2.2 Global PRRS Vaccines Revenue Forecast by Application (2027-2032)

4.2.3 Global PRRS Vaccines Price Forecast by Application (2027-2032)

4.3 New Sources of Growth in PRRS Vaccines Applications

5 Competition Landscape by Players

5.1 Global PRRS Vaccines Sales by Player (2021-2026)

5.2 Global Top PRRS Vaccines Players by Revenue (2021-2026)

5.3 Global PRRS Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3), based on PRRS Vaccines revenue as of 2025

5.4 Global PRRS Vaccines Average Price by Company (2021-2026)

5.5 Global Key Manufacturers of PRRS Vaccines, Manufacturing Sites & Headquarters

5.6 Global Key Manufacturers of PRRS Vaccines, Product Type & Application

5.7 Global Key Manufacturers of PRRS Vaccines, Date of Entry into This Industry

5.8 Manufacturers Mergers & Acquisitions, Expansion Plans

6 Regional Analysis

6.1 North America Market: Players, Segments, Downstream and Major Customers

6.1.1 North America PRRS Vaccines Sales by Company

6.1.1.1 North America PRRS Vaccines Sales by Company (2021-2026)

6.1.1.2 North America PRRS Vaccines Revenue by Company (2021-2026)

6.1.2 North America PRRS Vaccines Sales Breakdown by Type (2021-2026)

6.1.3 North America PRRS Vaccines Sales Breakdown by Application (2021-2026)

6.1.4 North America PRRS Vaccines Major Customers

6.1.5 North America Market Trends and Opportunities

6.2 Europe Market: Players, Segments, Downstream and Major Customers

6.2.1 Europe PRRS Vaccines Sales by Company

6.2.1.1 Europe PRRS Vaccines Sales by Company (2021-2026)

6.2.1.2 Europe PRRS Vaccines Revenue by Company (2021-2026)

6.2.2 Europe PRRS Vaccines Sales Breakdown by Type (2021-2026)

6.2.3 Europe PRRS Vaccines Sales Breakdown by Application (2021-2026)

6.2.4 Europe PRRS Vaccines Major Customers

6.2.5 Europe Market Trends and Opportunities

6.3 China Market: Players, Segments, Downstream and Major Customers

6.3.1 China PRRS Vaccines Sales by Company

6.3.1.1 China PRRS Vaccines Sales by Company (2021-2026)

6.3.1.2 China PRRS Vaccines Revenue by Company (2021-2026)

6.3.2 China PRRS Vaccines Sales Breakdown by Type (2021-2026)

6.3.3 China PRRS Vaccines Sales Breakdown by Application (2021-2026)

6.3.4 China PRRS Vaccines Major Customers

6.3.5 China Market Trends and Opportunities

6.4 Japan Market: Players, Segments, Downstream and Major Customers

6.4.1 Japan PRRS Vaccines Sales by Company

6.4.1.1 Japan PRRS Vaccines Sales by Company (2021-2026)

6.4.1.2 Japan PRRS Vaccines Revenue by Company (2021-2026)

6.4.2 Japan PRRS Vaccines Sales Breakdown by Type (2021-2026)

6.4.3 Japan PRRS Vaccines Sales Breakdown by Application (2021-2026)

6.4.4 Japan PRRS Vaccines Major Customers

6.4.5 Japan Market Trends and Opportunities

7 Company Profiles and Key Figures

7.1 China Animal Husbandry Co., Ltd.

7.1.1 China Animal Husbandry Co., Ltd. Company Information

7.1.2 China Animal Husbandry Co., Ltd. Business Overview

7.1.3 China Animal Husbandry Co., Ltd. PRRS Vaccines Sales, Revenue and Gross Margin (2021-2026)

7.1.4 China Animal Husbandry Co., Ltd. PRRS Vaccines Products Offered

7.1.5 China Animal Husbandry Co., Ltd. Recent Development

7.2 Boehringer Ingelheim

7.2.1 Boehringer Ingelheim Company Information

7.2.2 Boehringer Ingelheim Business Overview

7.2.3 Boehringer Ingelheim PRRS Vaccines Sales, Revenue and Gross Margin (2021-2026)

7.2.4 Boehringer Ingelheim PRRS Vaccines Products Offered

7.2.5 Boehringer Ingelheim Recent Development

7.3 MSD Animal Health

7.3.1 MSD Animal Health Company Information

7.3.2 MSD Animal Health Business Overview

7.3.3 MSD Animal Health PRRS Vaccines Sales, Revenue and Gross Margin (2021-2026)

7.3.4 MSD Animal Health PRRS Vaccines Products Offered

7.3.5 MSD Animal Health Recent Development

7.4 Sinopharm Animal Health

7.4.1 Sinopharm Animal Health Company Information

7.4.2 Sinopharm Animal Health Business Overview

7.4.3 Sinopharm Animal Health PRRS Vaccines Sales, Revenue and Gross Margin (2021-2026)

7.4.4 Sinopharm Animal Health PRRS Vaccines Products Offered

7.4.5 Sinopharm Animal Health Recent Development

7.5 Ceva

7.5.1 Ceva Company Information

7.5.2 Ceva Business Overview

7.5.3 Ceva PRRS Vaccines Sales, Revenue and Gross Margin (2021-2026)

7.5.4 Ceva PRRS Vaccines Products Offered

7.5.5 Ceva Recent Development

7.6 Ruipu Biological

7.6.1 Ruipu Biological Company Information

7.6.2 Ruipu Biological Business Overview

7.6.3 Ruipu Biological PRRS Vaccines Sales, Revenue and Gross Margin (2021-2026)

7.6.4 Ruipu Biological PRRS Vaccines Products Offered

7.6.5 Ruipu Biological Recent Development

7.7 Qilu Animal Health

7.7.1 Qilu Animal Health Company Information

7.7.2 Qilu Animal Health Business Overview

7.7.3 Qilu Animal Health PRRS Vaccines Sales, Revenue and Gross Margin (2021-2026)

7.7.4 Qilu Animal Health PRRS Vaccines Products Offered

7.7.5 Qilu Animal Health Recent Development

7.8 Dahuanong

7.8.1 Dahuanong Company Information

7.8.2 Dahuanong Business Overview

7.8.3 Dahuanong PRRS Vaccines Sales, Revenue and Gross Margin (2021-2026)

7.8.4 Dahuanong PRRS Vaccines Products Offered

7.8.5 Dahuanong Recent Development

7.9 CAVAC

7.9.1 CAVAC Company Information

7.9.2 CAVAC Business Overview

7.9.3 CAVAC PRRS Vaccines Sales, Revenue and Gross Margin (2021-2026)

7.9.4 CAVAC PRRS Vaccines Products Offered

7.9.5 CAVAC Recent Development

7.10 Komipharm

7.10.1 Komipharm Company Information

7.10.2 Komipharm Business Overview

7.10.3 Komipharm PRRS Vaccines Sales, Revenue and Gross Margin (2021-2026)

7.10.4 Komipharm PRRS Vaccines Products Offered

7.10.5 Komipharm Recent Development

7.11 Agrovet

7.11.1 Agrovet Company Information

7.11.2 Agrovet Business Overview

7.11.3 Agrovet PRRS Vaccines Sales, Revenue and Gross Margin (2021-2026)

7.11.4 Agrovet PRRS Vaccines Products Offered

7.11.5 Agrovet Recent Development

7.12 Bioveta

7.12.1 Bioveta Company Information

7.12.2 Bioveta Business Overview

7.12.3 Bioveta PRRS Vaccines Sales, Revenue and Gross Margin (2021-2026)

7.12.4 Bioveta PRRS Vaccines Products Offered

7.12.5 Bioveta Recent Development

7.13 Jinyu

7.13.1 Jinyu Company Information

7.13.2 Jinyu Business Overview

7.13.3 Jinyu PRRS Vaccines Sales, Revenue and Gross Margin (2021-2026)

7.13.4 Jinyu PRRS Vaccines Products Offered

7.13.5 Jinyu Recent Development

7.14 Phibro Animal Health

7.14.1 Phibro Animal Health Company Information

7.14.2 Phibro Animal Health Business Overview

7.14.3 Phibro Animal Health PRRS Vaccines Sales, Revenue and Gross Margin (2021-2026)

7.14.4 Phibro Animal Health PRRS Vaccines Products Offered

7.14.5 Phibro Animal Health Recent Development

7.15 Tiankang

7.15.1 Tiankang Company Information

7.15.2 Tiankang Business Overview

7.15.3 Tiankang PRRS Vaccines Sales, Revenue and Gross Margin (2021-2026)

7.15.4 Tiankang PRRS Vaccines Products Offered

7.15.5 Tiankang Recent Development

7.16 Zoetis

7.16.1 Zoetis Company Information

7.16.2 Zoetis Business Overview

7.16.3 Zoetis PRRS Vaccines Sales, Revenue and Gross Margin (2021-2026)

7.16.4 Zoetis PRRS Vaccines Products Offered

7.16.5 Zoetis Recent Development

7.17 Yongshun Biological

7.17.1 Yongshun Biological Company Information

7.17.2 Yongshun Biological Business Overview

7.17.3 Yongshun Biological PRRS Vaccines Sales, Revenue and Gross Margin (2021-2026)

7.17.4 Yongshun Biological PRRS Vaccines Products Offered

7.17.5 Yongshun Biological Recent Development

7.18 Pulike Biological

7.18.1 Pulike Biological Company Information

7.18.2 Pulike Biological Business Overview

7.18.3 Pulike Biological PRRS Vaccines Sales, Revenue and Gross Margin (2021-2026)

7.18.4 Pulike Biological PRRS Vaccines Products Offered

7.18.5 Pulike Biological Recent Development

8 PRRS Vaccines Manufacturing Cost Analysis

8.1 PRRS Vaccines Key Raw Materials Analysis

8.1.1 Key Raw Materials

8.1.2 Key Suppliers of Raw Materials

8.2 Manufacturing Cost Structure

8.3 Manufacturing Process Analysis of PRRS Vaccines

8.4 PRRS Vaccines Industrial Chain Analysis

9 Marketing Channels, Distributors and Customers

9.1 Marketing Channels

9.2 PRRS Vaccines Distributors List

9.3 PRRS Vaccines Customers

10 PRRS Vaccines Market Dynamics

10.1 PRRS Vaccines Industry Trends

10.2 PRRS Vaccines Market Drivers

10.3 PRRS Vaccines Market Challenges

10.4 PRRS Vaccines Market Restraints

11 Research Findings and Conclusion

12 Appendix

12.1 Research Methodology

12.1.1 Methodology/Research Approach

12.1.1.1 Research Programs/Design

12.1.1.2 Market Size Estimation

12.1.1.3 Market Breakdown and Data Triangulation

12.1.2 Data Source

12.1.2.1 Secondary Sources

12.1.2.2 Primary Sources

12.2 Author Details

12.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Global PRRS Vaccines Sales (US$ Million) Growth Rate by Type (2021, 2025 & 2032)

Table 2. Global PRRS Vaccines Sales (US$ Million) Comparison by Application (2021, 2025 & 2032)

Table 3. Global Market PRRS Vaccines Market Size (US$ Million) by Region:2021 VS 2025 VS 2032

Table 4. Global PRRS Vaccines Sales (K Units) by Region (2021-2026)

Table 5. Global PRRS Vaccines Sales Market Share by Region (2021-2026)

Table 6. Global PRRS Vaccines Revenue (US$ Million) Market Share by Region (2021-2026)

Table 7. Global PRRS Vaccines Revenue Share by Region (2021-2026)

Table 8. Global PRRS Vaccines Sales (K Units) Forecast by Region (2027-2032)

Table 9. Global PRRS Vaccines Sales Market Share Forecast by Region (2027-2032)

Table 10. Global PRRS Vaccines Revenue (US$ Million) Forecast by Region (2027-2032)

Table 11. Global PRRS Vaccines Revenue Share Forecast by Region (2027-2032)

Table 12. Global PRRS Vaccines Sales by Type (K Units) & (2021-2026)

Table 13. Global PRRS Vaccines Sales Share by Type (2021-2026)

Table 14. Global PRRS Vaccines Revenue by Type (US$ Million) & (2021-2026)

Table 15. Global PRRS Vaccines Average Price by Type (USD/Unit) & (2021-2026)

Table 16. Global PRRS Vaccines Sales by Type (K Units) & (2027-2032)

Table 17. Global PRRS Vaccines Revenue by Type (US$ Million) & (2027-2032)

Table 18. Global PRRS Vaccines Average Price by Type (USD/Unit) & (2027-2032)

Table 19. Representative Players of Each Type

Table 20. Global PRRS Vaccines Sales by Application (K Units) & (2021-2026)

Table 21. Global PRRS Vaccines Sales Share by Application (2021-2026)

Table 22. Global PRRS Vaccines Revenue by Application (US$ Million) & (2021-2026)

Table 23. Global PRRS Vaccines Average Price by Application (USD/Unit) & (2021-2026)

Table 24. Global PRRS Vaccines Sales by Application (K Units) & (2027-2032)

Table 25. Global PRRS Vaccines Revenue Market Share by Application (US$ Million) & (2027-2032)

Table 26. Global PRRS Vaccines Average Price by Application (USD/Unit) & (2027-2032)

Table 27. New Sources of Growth in PRRS Vaccines Applications

Table 28. Global PRRS Vaccines Sales by Company (K Units) & (2021-2026)

Table 29. Global PRRS Vaccines Sales Share by Company (2021-2026)

Table 30. Global PRRS Vaccines Revenue by Company (US$ Million) & (2021-2026)

Table 31. Global PRRS Vaccines Revenue Share by Company (2021-2026)

Table 32. Global PRRS Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PRRS Vaccines as of 2025)

Table 33. Global Market PRRS Vaccines Average Price by Company (USD/Unit) & (2021-2026)

Table 34. Global Key Manufacturers of PRRS Vaccines, Manufacturing Sites & Headquarters

Table 35. Global Key Manufacturers of PRRS Vaccines, Product Type & Application

Table 36. Global Key Manufacturers of PRRS Vaccines, Date of Entry into This Industry

Table 37. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 38. North America PRRS Vaccines Sales by Company (2021-2026) & (K Units)

Table 39. North America PRRS Vaccines Sales Market Share by Company (2021-2026)

Table 40. North America PRRS Vaccines Revenue by Company (2021-2026) & (US$ Million)

Table 41. North America PRRS Vaccines Revenue Market Share by Company (2021-2026)

Table 42. North America PRRS Vaccines Sales by Type (2021-2026) & (K Units)

Table 43. North America PRRS Vaccines Sales Market Share by Type (2021-2026)

Table 44. North America PRRS Vaccines Sales by Application (2021-2026) & (K Units)

Table 45. North America PRRS Vaccines Sales Market Share by Application (2021-2026)

Table 46. Europe PRRS Vaccines Sales by Company (2021-2026) & (K Units)

Table 47. Europe PRRS Vaccines Sales Market Share by Company (2021-2026)

Table 48. Europe PRRS Vaccines Revenue by Company (2021-2026) & (US$ Million)

Table 49. Europe PRRS Vaccines Revenue Market Share by Company (2021-2026)

Table 50. Europe PRRS Vaccines Sales by Type (2021-2026) & (K Units)

Table 51. Europe PRRS Vaccines Sales Market Share by Type (2021-2026)

Table 52. Europe PRRS Vaccines Sales by Application (2021-2026) & (K Units)

Table 53. Europe PRRS Vaccines Sales Market Share by Application (2021-2026)

Table 54. China PRRS Vaccines Sales by Company (2021-2026) & (K Units)

Table 55. China PRRS Vaccines Sales Market Share by Company (2021-2026)

Table 56. China PRRS Vaccines Revenue by Company (2021-2026) & (US$ Million)

Table 57. China PRRS Vaccines Revenue Market Share by Company (2021-2026)

Table 58. China PRRS Vaccines Sales by Type (2021-2026) & (K Units)

Table 59. China PRRS Vaccines Sales Market Share by Type (2021-2026)

Table 60. China PRRS Vaccines Sales by Application (2021-2026) & (K Units)

Table 61. China PRRS Vaccines Sales Market Share by Application (2021-2026)

Table 62. Japan PRRS Vaccines Sales by Company (2021-2026) & (K Units)

Table 63. Japan PRRS Vaccines Sales Market Share by Company (2021-2026)

Table 64. Japan PRRS Vaccines Revenue by Company (2021-2026) & (US$ Million)

Table 65. Japan PRRS Vaccines Revenue Market Share by Company (2021-2026)

Table 66. Japan PRRS Vaccines Sales by Type (2021-2026) & (K Units)

Table 67. Japan PRRS Vaccines Sales Market Share by Type (2021-2026)

Table 68. Japan PRRS Vaccines Sales by Application (2021-2026) & (K Units)

Table 69. Japan PRRS Vaccines Sales Market Share by Application (2021-2026)

Table 70. China Animal Husbandry Co., Ltd. Company Information

Table 71. China Animal Husbandry Co., Ltd. Description and Business Overview

Table 72. China Animal Husbandry Co., Ltd. PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)

Table 73. China Animal Husbandry Co., Ltd. PRRS Vaccines Product

Table 74. China Animal Husbandry Co., Ltd. Recent Development

Table 75. Boehringer Ingelheim Company Information

Table 76. Boehringer Ingelheim Description and Business Overview

Table 77. Boehringer Ingelheim PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)

Table 78. Boehringer Ingelheim PRRS Vaccines Product

Table 79. Boehringer Ingelheim Recent Development

Table 80. MSD Animal Health Company Information

Table 81. MSD Animal Health Description and Business Overview

Table 82. MSD Animal Health PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)

Table 83. MSD Animal Health PRRS Vaccines Product

Table 84. MSD Animal Health Recent Development

Table 85. Sinopharm Animal Health Company Information

Table 86. Sinopharm Animal Health Description and Business Overview

Table 87. Sinopharm Animal Health PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)

Table 88. Sinopharm Animal Health PRRS Vaccines Product

Table 89. Sinopharm Animal Health Recent Development

Table 90. Ceva Company Information

Table 91. Ceva Description and Business Overview

Table 92. Ceva PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)

Table 93. Ceva PRRS Vaccines Product

Table 94. Ceva Recent Development

Table 95. Ruipu Biological Company Information

Table 96. Ruipu Biological Description and Business Overview

Table 97. Ruipu Biological PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)

Table 98. Ruipu Biological PRRS Vaccines Product

Table 99. Ruipu Biological Recent Development

Table 100. Qilu Animal Health Company Information

Table 101. Qilu Animal Health Description and Business Overview

Table 102. Qilu Animal Health PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)

Table 103. Qilu Animal Health PRRS Vaccines Product

Table 104. Qilu Animal Health Recent Development

Table 105. Dahuanong Company Information

Table 106. Dahuanong Description and Business Overview

Table 107. Dahuanong PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)

Table 108. Dahuanong PRRS Vaccines Product

Table 109. Dahuanong Recent Development

Table 110. CAVAC Company Information

Table 111. CAVAC Description and Business Overview

Table 112. CAVAC PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)

Table 113. CAVAC PRRS Vaccines Product

Table 114. CAVAC Recent Development

Table 115. Komipharm Company Information

Table 116. Komipharm Description and Business Overview

Table 117. Komipharm PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)

Table 118. Komipharm PRRS Vaccines Product

Table 119. Komipharm Recent Development

Table 120. Agrovet Company Information

Table 121. Agrovet Description and Business Overview

Table 122. Agrovet PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)

Table 123. Agrovet PRRS Vaccines Product

Table 124. Agrovet Recent Development

Table 125. Bioveta Company Information

Table 126. Bioveta Description and Business Overview

Table 127. Bioveta PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)

Table 128. Bioveta PRRS Vaccines Product

Table 129. Bioveta Recent Development

Table 130. Jinyu Company Information

Table 131. Jinyu Description and Business Overview

Table 132. Jinyu PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)

Table 133. Jinyu PRRS Vaccines Product

Table 134. Jinyu Recent Development

Table 135. Phibro Animal Health Company Information

Table 136. Phibro Animal Health Description and Business Overview

Table 137. Phibro Animal Health PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)

Table 138. Phibro Animal Health PRRS Vaccines Product

Table 139. Phibro Animal Health Recent Development

Table 140. Tiankang Company Information

Table 141. Tiankang Description and Business Overview

Table 142. Tiankang PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)

Table 143. Tiankang PRRS Vaccines Product

Table 144. Tiankang Recent Development

Table 145. Zoetis Company Information

Table 146. Zoetis Description and Business Overview

Table 147. Zoetis PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)

Table 148. Zoetis PRRS Vaccines Product

Table 149. Zoetis Recent Development

Table 150. Yongshun Biological Company Information

Table 151. Yongshun Biological Description and Business Overview

Table 152. Yongshun Biological PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)

Table 153. Yongshun Biological PRRS Vaccines Product

Table 154. Yongshun Biological Recent Development

Table 155. Pulike Biological Company Information

Table 156. Pulike Biological Description and Business Overview

Table 157. Pulike Biological PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)

Table 158. Pulike Biological PRRS Vaccines Product

Table 159. Pulike Biological Recent Development

Table 160. Production Base and Market Concentration Rate of Raw Material

Table 161. Key Suppliers of Raw Materials

Table 162. PRRS Vaccines Distributors List

Table 163. PRRS Vaccines Customers List

Table 164. PRRS Vaccines Market Trends

Table 165. PRRS Vaccines Market Drivers

Table 166. PRRS Vaccines Market Challenges

Table 167. PRRS Vaccines Market Restraints

Table 168. Research Programs/Design for This Report

Table 169. Key Data Information from Secondary Sources

Table 170. Key Data Information from Primary Sources

List of Figures

Figure 1. PRRS Vaccines Product Picture

Figure 2. Global PRRS Vaccines Sales (US$ Million) by Type (2021, 2025 & 2032)

Figure 3. Global PRRS Vaccines Sales Market Share by Type in 2025 & 2032

Figure 4. Live Vaccines Product Picture

Figure 5. Killed Vaccines Product Picture

Figure 6. Global PRRS Vaccines Sales (US$ Million) by Application (2021, 2025 & 2032)

Figure 7. Global PRRS Vaccines Sales Market Share by Application in 2025 & 2032

Figure 8. Government Tender Examples

Figure 9. Market Sales Examples

Figure 10. Global PRRS Vaccines Sales, (US$ Million), 2021 VS 2025 VS 2032

Figure 11. Global PRRS Vaccines Sales Growth Rate (2021-2032) & (US$ Million)

Figure 12. Global PRRS Vaccines Sales (K Units) Growth Rate (2021-2032)

Figure 13. Global PRRS Vaccines Price Trends Growth Rate (2021-2032) & (USD/Unit)

Figure 14. PRRS Vaccines Report Years Considered

Figure 15. Global Market PRRS Vaccines Market Size (US$ Million) by Region:2021 VS 2025 VS 2032

Figure 16. Global PRRS Vaccines Revenue Market Share by Region: 2021 VS 2025

Figure 17. North America PRRS Vaccines Revenue (US$ Million) Growth Rate (2021-2032)

Figure 18. North America PRRS Vaccines Sales (K Units) Growth Rate (2021-2032)

Figure 19. Europe PRRS Vaccines Revenue (US$ Million) Growth Rate (2021-2032)

Figure 20. Europe PRRS Vaccines Sales (K Units) Growth Rate (2021-2032)

Figure 21. China PRRS Vaccines Revenue (US$ Million) Growth Rate (2021-2032)

Figure 22. China PRRS Vaccines Sales (K Units) Growth Rate (2021-2032)

Figure 23. Japan PRRS Vaccines Revenue (US$ Million) Growth Rate (2021-2032)

Figure 24. Japan PRRS Vaccines Sales (K Units) Growth Rate (2021-2032)

Figure 25. Global PRRS Vaccines Revenue Share by Type (2021-2026)

Figure 26. Global PRRS Vaccines Sales Share by Type (2027-2032)

Figure 27. Global PRRS Vaccines Revenue Share by Type (2027-2032)

Figure 28. Global PRRS Vaccines Revenue Share by Application (2021-2026)

Figure 29. Global PRRS Vaccines Revenue Market Share by Application in 2021 & 2025

Figure 30. Global PRRS Vaccines Sales Share by Application (2027-2032)

Figure 31. Global PRRS Vaccines Revenue Share by Application (2027-2032)

Figure 32. Global PRRS Vaccines Sales Share by Company (2025)

Figure 33. Global PRRS Vaccines Revenue Share by Company (2025)

Figure 34. Global 5 Largest PRRS Vaccines Players Market Share by Revenue in PRRS Vaccines: 2021 & 2025

Figure 35. PRRS Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025

Figure 36. Manufacturing Cost Structure of PRRS Vaccines

Figure 37. Manufacturing Process Analysis of PRRS Vaccines

Figure 38. PRRS Vaccines Industrial Chain

Figure 39. Channels of Distribution (Direct Vs Distribution)

Figure 40. Distributors Profiles

Figure 41. Bottom-up and Top-down Approaches for This Report

Figure 42. Data Triangulation

Figure 43. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

What was the global market size of PRRS Vaccines in 2032? zhanKai

The global market size of PRRS Vaccines in 2032 was 543 Million USD.

Which companies rank high in the global PRRS Vaccines market? shouQi

Which region is expected to have the highest market share? shouQi

What was the global market size of PRRS Vaccines in 2026? shouQi

What is the annual compound growth rate of the global PRRS Vaccines market size from 2026 to 2032? shouQi

Related Reports

Global PRRS Vaccines Market Outlook, In‑Depth Analysis & Forecast to 2032
The global PRRS Vaccines market is projected to grow from US$ 429 million in 2025 to US$ 543 million by 2032, at a CAGR of 3.5% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2026-03-09
Pages: 179
USD 4900.00
(Single User License)
PRRS Vaccines- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for PRRS Vaccines was estimated to be worth US$ 429 million in 2025 and is projected to reach US$ 543 million, growing at a CAGR of 3.5% from 2026 to 2032.
Published Date: 2026-03-05
Pages: 131
USD 3950.00
(Single User License)
Global PRRS Vaccines Market Research Report 2026
The global PRRS Vaccines market was valued at US$ 429 million in 2025 and is anticipated to reach US$ 543 million by 2032, at a CAGR of 3.5% from 2026 to 2032.
Published Date: 2026-03-05
Pages: 146
USD 2900.00
(Single User License)
Global PRRS Vaccines Market Outlook, In‑Depth Analysis & Forecast to 2031
The global PRRS Vaccines market is projected to grow from US$ 410 million in 2024 to US$ 527 million by 2031, at a CAGR of 3.5% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2025-10-30
Pages: 176
USD 4900.00
(Single User License)
PRRS Vaccines - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for PRRS Vaccines was estimated to be worth US$ 410 million in 2024 and is forecast to a readjusted size of US$ 527 million by 2031 with a CAGR of 3.5% during the forecast period 2025-2031.
Published Date: 2025-05-23
Pages: 134
USD 3950.00
(Single User License)
Global PRRS Vaccines Market Insights, Forecast to 2031
The global PRRS Vaccines market is projected to grow from US$ 429 million in 2025 to US$ 527 million by 2031, at a Compound Annual Growth Rate (CAGR) of 3.5% during the forecast period.
Published Date: 2025-05-23
Pages: 175
USD 4900.00
(Single User License)
Global PRRS Vaccines Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global PRRS Vaccines market size was US$ 410 million in 2024 and is forecast to a readjusted size of US$ 527 million by 2031 with a CAGR of 3.5% during the forecast period 2025-2031.
Published Date: 2025-05-23
Pages: 109
USD 4250.00
(Single User License)
Global PRRS Vaccines Market Research Report 2025
The global market for PRRS Vaccines was valued at US$ 410 million in the year 2024 and is projected to reach a revised size of US$ 527 million by 2031, growing at a CAGR of 3.5% during the forecast period.
Published Date: 2025-05-23
Pages: 115
USD 2900.00
(Single User License)
PRRS Vaccines- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for PRRS Vaccines was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-02-25
Pages: 140
USD 3950.00
(Single User License)
Global PRRS Vaccines Market Insights, Forecast to 2030
There are two types of PRRS vaccines that are commercially available. One is a modified-live virus (MLV) vaccine and the other is a killed virus (KV) vaccine. PRRS MLV vaccine is well recognized for its protective efficacy against PRRSV that are genetically homologous to the vaccine virus.
Published Date: 2024-04-22
Pages: 117
USD 4900.00
(Single User License)

Global PRRS Vaccines Market Outlook, In‑Depth Analysis & Forecast to 2032
The global PRRS Vaccines market is projected to grow from US$ 429 million in 2025 to US$ 543 million by 2032, at a CAGR of 3.5% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2026-03-09
Pages: 179
USD 4900.00 (Single User License)
PRRS Vaccines- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for PRRS Vaccines was estimated to be worth US$ 429 million in 2025 and is projected to reach US$ 543 million, growing at a CAGR of 3.5% from 2026 to 2032.
Published: 2026-03-05
Pages: 131
USD 3950.00 (Single User License)
Global PRRS Vaccines Market Research Report 2026
The global PRRS Vaccines market was valued at US$ 429 million in 2025 and is anticipated to reach US$ 543 million by 2032, at a CAGR of 3.5% from 2026 to 2032.
Published: 2026-03-05
Pages: 146
USD 2900.00 (Single User License)
Global PRRS Vaccines Market Outlook, In‑Depth Analysis & Forecast to 2031
The global PRRS Vaccines market is projected to grow from US$ 410 million in 2024 to US$ 527 million by 2031, at a CAGR of 3.5% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2025-10-30
Pages: 176
USD 4900.00 (Single User License)
PRRS Vaccines - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for PRRS Vaccines was estimated to be worth US$ 410 million in 2024 and is forecast to a readjusted size of US$ 527 million by 2031 with a CAGR of 3.5% during the forecast period 2025-2031.
Published: 2025-05-23
Pages: 134
USD 3950.00 (Single User License)
Global PRRS Vaccines Market Insights, Forecast to 2031
The global PRRS Vaccines market is projected to grow from US$ 429 million in 2025 to US$ 527 million by 2031, at a Compound Annual Growth Rate (CAGR) of 3.5% during the forecast period.
Published: 2025-05-23
Pages: 175
USD 4900.00 (Single User License)
Global PRRS Vaccines Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global PRRS Vaccines market size was US$ 410 million in 2024 and is forecast to a readjusted size of US$ 527 million by 2031 with a CAGR of 3.5% during the forecast period 2025-2031.
Published: 2025-05-23
Pages: 109
USD 4250.00 (Single User License)
Global PRRS Vaccines Market Research Report 2025
The global market for PRRS Vaccines was valued at US$ 410 million in the year 2024 and is projected to reach a revised size of US$ 527 million by 2031, growing at a CAGR of 3.5% during the forecast period.
Published: 2025-05-23
Pages: 115
USD 2900.00 (Single User License)
PRRS Vaccines- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for PRRS Vaccines was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-02-25
Pages: 140
USD 3950.00 (Single User License)
Global PRRS Vaccines Market Insights, Forecast to 2030
There are two types of PRRS vaccines that are commercially available. One is a modified-live virus (MLV) vaccine and the other is a killed virus (KV) vaccine. PRRS MLV vaccine is well recognized for its protective efficacy against PRRSV that are genetically homologous to the vaccine virus.
Published: 2024-04-22
Pages: 117
USD 4900.00 (Single User License)